# Evaluate the Safety and Efficacy of Saroglitazar Mg in Patients With Fasting Triglyceride ≥500 mg/dL and ≤1500 mg/dL

Study · id `cardio:ct-nct03097107` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03097107](<https://clinicaltrials.gov/study/NCT03097107>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT03097107

Browse, organ or system: Metabolism  
Browse, condition area: Risk and prevention; Diabetes and metabolic disease  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is suspended. It plans to enroll 124 participants.

## Technical summary

Registry record NCT03097107. Randomized; quadruple masking; primary purpose treatment. Start 2017-04-06 (actual); primary completion 2023-12 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 124 participants (planned count; ClinicalTrials.gov record NCT03097107, source copy `cardio:ctgov-nct03097107-2023-02-08`, retrieved 2026-10-31)
- Started: 2017-04-06 (actual) (ClinicalTrials.gov record NCT03097107, source copy `cardio:ctgov-nct03097107-2023-02-08`, retrieved 2026-10-31)
- Primary completion: 2023-12 (anticipated) (ClinicalTrials.gov record NCT03097107, source copy `cardio:ctgov-nct03097107-2023-02-08`, retrieved 2026-10-31)
- Completion: 2024-01 (anticipated) (ClinicalTrials.gov record NCT03097107, source copy `cardio:ctgov-nct03097107-2023-02-08`, retrieved 2026-10-31)
- Countries: United States (ClinicalTrials.gov record NCT03097107, source copy `cardio:ctgov-nct03097107-2023-02-08`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "SUSPENDED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03097107-2023-02-08`, retrieved 2026-10-31)

## The registry's words

- Brief title: Evaluate the Safety and Efficacy of Saroglitazar Mg in Patients With Fasting Triglyceride ≥500 mg/dL and ≤1500 mg/dL
- Condition: Dyslipidemias
- Intervention (Drug): Saroglitazar Magnesium 1 mg
- Intervention (Drug): Saroglitazar Magnesium 2 mg
- Intervention (Drug): Saroglitazar Magnesium 4 mg
- Intervention (Drug): Placebo
- Lead sponsor: Zydus Therapeutics Inc.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)
- Registry condition terms include this condition: High triglycerides (`cardio:hypertriglyceridemia`)

## Provenance

Content hash: 971e71e40c00a7d6270f3118b94eb2b3839e1e5f22b58293f4766474b8e27fcd
Last substantive edit: 2026-10-31
Evidence last checked: Not recorded
